A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04640272
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Valley Retina Institute, McAllen, Texas, United States
🇺🇸Retinal Medical Consultants Group, Sacramento, California, United States
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 94
- Registration Number
- NCT04200248
- Locations
- 🇺🇸
Bay Area Retina Associates, Walnut Creek, California, United States
🇺🇸Valley Retina Institute, PA, McAllen, Texas, United States
🇺🇸Advanced Research, LLC, Coral Springs, Florida, United States
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
Phase 1
Completed
- Conditions
- Age-related Macular Degeneration
- Interventions
- Drug: RBM-007 Injectable Solution
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 9
- Registration Number
- NCT03633084
- Locations
- 🇺🇸
Retinal Consultants Medical Group, Sacramento, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
© Copyright 2025. All Rights Reserved by MedPath